[breadcrumb_custom]

Cytek BioSciences Inc (NASDAQ:CTKB) At $8.28: What To Do?

In last trading session, Cytek BioSciences Inc (NASDAQ:CTKB) saw 0.43 million shares changing hands with its beta currently measuring 1.45. Company’s recent per share price level of $8.28 trading at $0.1 or 1.22% at ring of the bell on the day assigns it a market valuation of $1.12B. That closing price of CTKB’s stock is at a discount of -66.3% from its 52-week high price of $13.77 and is indicating a premium of 54.11% from its 52-week low price of $3.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 939.73K if we extend that period to 3-months.

Cytek BioSciences Inc (NASDAQ:CTKB) trade information

Upright in the green during last session for gaining 1.22%, in the last five days CTKB remained trading in the green while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $8.28 price level, adding 1.19% to its value on the day. Cytek BioSciences Inc’s shares saw a change of -9.21% in year-to-date performance and have moved 5.08% in past 5-day. Cytek BioSciences Inc (NASDAQ:CTKB) showed a performance of -2.36% in past 30-days. Number of shares sold short was 7.64 million shares which calculate 7.38 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Cytek BioSciences Inc (CTKB) estimates and forecasts

Statistics highlight that Cytek BioSciences Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -9.01% of value to its shares in past 6 months, showing an annual growth rate of -60.00% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -100.00% in the current quarter and calculating -20.00% decrease in the next quarter. This year revenue growth is estimated to rise 16.40% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $56.58 million for the same. And 5 analysts are in estimates of company making revenue of $43.12 million in the next quarter that will end on Mar 2024. Company posted $48.33 million and $37.09 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 17.10% while estimating it to be 16.30% for the next quarter.

CTKB Dividends

Cytek BioSciences Inc is more likely to be releasing its next quarterly report on February 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Cytek BioSciences Inc (NASDAQ:CTKB)’s Major holders

Insiders are in possession of 8.52% of company’s total shares while institution are holding 62.34 percent of that, with stock having share float percentage of 68.14%. Investors also watch the number of corporate investors in a company very closely, which is 62.34% institutions for Cytek BioSciences Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at CTKB for having 16.77 million shares of worth $138.86 million. And as of Sep 29, 2023, it was holding 12.37% of the company’s outstanding shares.

The second largest institutional holder is Brown Capital Management, LLC, which was holding about 13.56 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 10.00% of outstanding shares, having a total worth of $112.28 million.

On the other hand, Brown Capital Management Small Company Fund and iShares Core S&P Smallcap ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2023, the former fund manager was holding 7.05 million shares of worth $58.35 million or 5.20% of the total outstanding shares. The later fund manager was in possession of 6.63 million shares on Dec 30, 2023, making its stake of worth around $54.87 million in the company or a holder of 4.89% of company’s stock.

On Key

Related Posts